Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Hemopurifier relationship established with Kentucky Bioprocessing

Aethlon Medical : 23 September, 2009  (Company News)
Commercial production deal between Aethlon Medical and Kentucky Bioprocessing for Hemopurifier immobilised active affinity agents
Aethlon Medical has initiated a relationship with Kentucky Bioprocessing to establish processes to support large-scale production of the active affinity agents immobilized within the Aethlon Hemopurifier. Such affinity agents allow the Hemopurifer to selectively capture a broad-spectrum of viruses from blood and other fluids. The Hemopurifier is the first-in-class medical device to selectively adsorb viruses and immunosuppressive particles from the bloodstream.

'The relationship with Kentucky Bioprocessing represents an important step towards establishing the long-term commercial feasibility of our Hemopurifier, stated Aethlon Medical CEO, Jim Joyce. 'Beyond a significant cost reduction of our affinity agents, the relationship offers large yield production potential in time frames that could improve our response capability against viral outbreaks, including unforeseen bioterror and pandemic threats,' concluded Joyce.

As part of the relationship, Kentucky Bioprocessing will establish and confirm the sequence of Aethlon's affinity agents and then conduct optimization studies to insure agent purity. The affinity agents will then be transported as cloned proteins to be expressed in and extracted from tobacco plants as a strategy to maximize production yields.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo